Drug discovery

#Drug discovery #Fragment-based drug discovery #Webinar

Webinar: Learn how to accelerate the early stages of drug discovery

Fragment-based drug discovery (FBDD) offers an efficient route to explore chemical space, but critical bottlenecks remain. Commercial fragment libraries are either too large to screen routinely with biophysical methods or too small to capture sufficient chemical diversity for challenging targets. Moreover, fragment expansions into focused compound collections lacks streamlined, integrated… Read More

#News

Automation
#Automation #Automation / robotics #Drug discovery #Lab technology #Webinar

Webinar: Moving beyond siloed automation with an orchestrated lab

Many laboratories have invested in automation, yet workflows often remain fragmented, with disconnected instruments, data, and processes creating inefficiencies and limiting scalability. As scientific workflows grow more complex, automation alone is no longer enough. Leading labs are now embracing orchestration, the coordination of instruments, robotics, software, data, and people across… Read More

#News

#Cancer research #Clinical trial #Drug discovery #Francis Crick Institute #Funding #Genetic profiling #GLP-1 #Lung cancer #MHRA #National Institute for Health and Care Research #Obesity #Oncology #Rare disease #Regulatory #The Royal Marsden NHS Foundation Trust #University College London #Weight loss

DDW Highlights: 16 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, new research showed anti-IL-1β drugs could prevent lung cancer. Elsewhere, the… Read More

#Podcasts

#Drug discovery #Guide #Nanopore sequencing

Guide: One solution – from R&D, to QC

Comprehensive sequencing is now an essential checkpoint at every stage in drug development — discover how Oxford Nanopore sequencing can support the development of your cell, gene, and RNA therapy drug modalities. In this Guide, you will learn: How nanopore sequencing enables whole plasmid characterisation, delivering complete confidence in your… Read More

#News

#Biosafety testing #Drug discovery #Next generation sequencing #Webinar

Webinar: Consolidate multiple assays into a single, comprehensive AVA test

Biopharmaceutical manufacturers are under increasing pressure to deliver safe, reliable products at speed – yet adventitious viral agent (AVA) testing remains one of the most significant bottlenecks in the quality control process. In this on-demand webinar, ViruSure, a global leader in pathogen safety testing, shares how it… Read More

Webinar date:
Supported by Oxford Nanopore Technologies and ViruSure
#News

#Champions Oncology #Drug discovery #KRAS #Oncology #Patient-derived tumour models #Tumour models #Webinar

Decoding Pan-RAS(ON) inhibitor activity across KRAS models: Webinar

KRAS mutations are among the most prevalent oncogenic drivers in solid tumours, yet predicting which patients will respond to targeted therapy — and understanding why resistance inevitably emerges — remains one of the central challenges in oncology drug development. ‘Cracking KRAS: Decoding Sensitivity and Resistance to Pan-RAS(ON) Inhibition Across Patient-Derived… Read More

#News

#Cancer research #Clinical trial #Drug discovery #Funding #Genetic profiling #GLP-1 #Lung cancer #MHRA #National Institute for Health and Care Research #Obesity #Oncology #Rare disease #Regulatory #The Francis Crick Institute #The Royal Marsden NHS Foundation Trust #University College London #Weight loss

This week in Drug Discovery (8 – 12 June) 

News round-up for 8 – 12 June by Bruno Quinney, Content Team at DDW.  This week, new research suggests anti-IL-1β drugs could prevent lung cancer. Elsewhere, the UK is set to benefit from specialised blood tests and funding for researchers.   The top stories:   … Read More

#News

#Cancer Research Horizons #CAR T-cell therapy #Drug discovery #Oncology #UK

On the Horizon – will In Vivo CAR-T fulfil its potential? 

DDW’s Maria Wallace attended Cancer Research Horizons’ On the Horizon breakfast event to learn more about the latest opportunities and challenges in cancer drug discovery and development.  Leading experts from academia, pharma, biotech and investment met in London, UK Thursday 11 June to discuss the potential of in vivo CAR-T therapies to transform the future of… Read More

#News

#AI #Drug discovery #Sygnature Discovery

DaltonTx launches AI drug discovery platform 

DaltonTx has launched an AI drug discovery platform which could help scientists “make better-informed decisions earlier in the discovery process”.  The platform, called Dalton, seeks to integrate agentic AI, human expertise and experimental data into a continuous learning engine.   DaltonTx says the platform links molecules, assays, models, experimental outcomes, project context and human decisions… Read More

#News

#Automation #Automation / robotics #Drug discovery #Lab technology #Webinar

Webinar – The orchestrated lab: Moving beyond siloed automation

Many laboratories have invested in automation, yet workflows often remain fragmented, with disconnected instruments, data, and processes creating inefficiencies and limiting scalability. As scientific workflows grow more complex, automation alone is no longer enough. Leading labs are now embracing orchestration, the coordination of instruments, robotics, software, data, and people across… Read More

#News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Drug discovery #Investment #Life sciences #Oncology

Bead BioPharma emerges from stealth with novel drug platform 

Bead BioPharma has emerged from stealth by submitting a patent for a novel cancer drug platform.  The life sciences company, backed by Archangels, submitted the patent in efforts to launch its formal entry into one of the most competitive sectors of global oncology.  Bead BioPharma is focused on antibody-drug conjugates (ADCs), a class of cancer therapies sometimes… Read More

#Business & Investment #News

#Drug discovery #Fragment-based drug discovery #Webinar

Webinar: Overcome critical bottlenecks in fragment-based drug discovery

Fragment-based drug discovery (FBDD) offers an efficient route to explore chemical space, but critical bottlenecks remain. Commercial fragment libraries are either too large to screen routinely with biophysical methods or too small to capture sufficient chemical diversity for challenging targets. Moreover, fragment expansions into focused compound collections lacks streamlined, integrated… Read More

#News

#CatSci #CRISPR #Drug development #Drug discovery #Life science #siRNA

From undruggable to inevitable

Dr Joe Renny, Head of Corporate Development, and Dr Simon Tyler, Chief Commercial Officer, CatSci, discuss the last 15 years of drug development, and what comes next. The American Cancer Society’s 2026 statistics tell a story that should be on the wall of every drug developer. Five-year survival for chronic… Read More

#Exclusive Content

Antibody discovery concept
#Artificial intelligence (AI) #Biologics #Drug discovery #Therapeutic Antibodies #Webinar

Webinar: Modernise and scale your antibody discovery programmes

Antibody discovery is being reshaped by two forces: an explosion of novel formats and the growing role of AI across the DBTL loop. But most teams are still running antibody programs on software that hasn’t kept pace with science, leaving data siloed and relationships missing. In this webinar, hosted by… Read More

Webinar date:
Supported by Benchling
#News